C12N 2501/056
Immunostimulating oligonucleotides
Official title: Immunostimulating oligonucleotides, e.g. CpG
C12N2501/056 (Immunostimulating oligonucleotides) appears on 41 US grants and 85 published applications in this corpus.
Search patents in C12N- Granted patents
- 41
- Published applications
- 85
- Assignees
- 62
- Inventors
- 158
- Latest grant
- 25 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1992 | 1 | 0 |
| 1993 | 0 | 0 |
| 1994 | 0 | 0 |
| 1995 | 0 | 0 |
| 1996 | 1 | 0 |
| 1997 | 0 | 0 |
| 1998 | 0 | 0 |
| 1999 | 0 | 0 |
| 2000 | 0 | 0 |
| 2001 | 0 | 0 |
| 2002 | 1 | 1 |
| 2003 | 0 | 3 |
| 2004 | 0 | 8 |
| 2005 | 1 | 3 |
| 2006 | 0 | 3 |
| 2007 | 1 | 3 |
| 2008 | 2 | 3 |
| 2009 | 0 | 3 |
| 2010 | 1 | 4 |
| 2011 | 4 | 2 |
| 2012 | 4 | 4 |
| 2013 | 3 | 3 |
| 2014 | 1 | 4 |
| 2015 | 0 | 2 |
| 2016 | 4 | 1 |
| 2017 | 4 | 4 |
| 2018 | 0 | 6 |
| 2019 | 1 | 5 |
| 2020 | 0 | 5 |
| 2021 | 1 | 3 |
| 2022 | 4 | 4 |
| 2023 | 3 | 4 |
| 2024 | 1 | 3 |
| 2025 | 2 | 3 |
| 2026 | 1 | 1 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Treatment of disc degenerative disease and stimulation of proteoglycan synthesis by fibroblast conditioned media and formulations thereof25 Aug 2026US 12,716,055 B2Fibrobiologics, Inc.
- Tumor-infiltrating lymphocytes for adoptive cell therapy6 May 2025US 12,291,724 B2H. Lee Moffitt Cancer Center and Research Institute, Inc.
- Methods of producing T cell populations enriched for stable regulatory T-cells14 Jan 2025US 12,195,724 B2The United States of America, as represented by the Secretary, Department of Health and Human Services
- Engraftable cell-based immunotherapy for long-term delivery of therapeutic proteins26 Mar 2024US 11,939,594 B2Seattle Children's Hospital
- Method for amplifying CD8+T cells and cell subpopulations thereof in-vitro3 Oct 2023US 11,773,373 B2Shanghai Innovative Chang'An Biological Technology Co., Ltd.
- Enrichment and expansion of chimeric antigen receptor t cells using antigen-presenting biomaterials1 Oct 2026US 2026/0297520 A1The Regents of the University of California
- Sirpa deficient macrophages for treating cancer30 Oct 2025US 2025/0333698 A1Georgia State University Research Foundation, Inc.
- Cells with increased immuno-regulatory properties and methods for their use and manufacture30 Oct 2025US 2025/0333702 A1Children's Medical Center Corporation
- Cells with increased immuno-regulatory properties and methods for their use and manufacture27 Mar 2025US 2025/0101381 A1Children's Medical Center Corporation
- Cancer therapies comprising peptide loaded cxcr3- and ccr5-inducing dendritic cells and chemokine modulatory agents12 Sep 2024US 2024/0299544 A1H. Lee Moffitt Cancer Center and Research Institute, Inc.
Most cited
By later US patents
- Immunostimulatory nucleic acid molecules for activating dendritic cells265US 6,429,199 B1University of Iowa Research Foundation · 2002
- Methods related to immunostimulatory nucleic acid-induced interferon110US 6,949,520 B1Coley Pharmaceutical GmbH · 2005
- Method for proliferation of antigen-specific T cells54US 9,476,028 B2Immunicum AB · 2016
- Methods related to immunostimulatory nucleic acid-induced interferon42US 7,776,344 B2Coley Pharmaceutical GmbH · 2010
- Method for rapid generation of mature dendritic cells33US 7,354,909 B2The United States of America, as represented by the Secretary, Department of Health and Human Services · 2008